Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
CA 2400823 A1 · Owner: Universiteit Utrecht · Inventors: Gebbink, Martijn Frans Ben Gerard; Voest, Emile Eugene
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof capable of providing , enhanced levels of plasmin in a mammalian through tPA mediated plasminogen activation for use as a pharmaceutical. The invention further provides use of a proteinaceous molecule according to the invention for the preparation of a medicament for the treatment of diseases related with angiogenesis and/or inflammatory disorders and/or conformational disorders and/or ageing. Furthermore the invention provides a proteinaceous molecule to suppress tumor growth, to regress established tumors, to degrade amyloid-.beta. and to inhibit …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 26, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 26, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 26, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.